Crestor loses market share following AHA journal article

Share this article:

AstraZeneca's Crestor lost U.S. market share following the publication of a negative report in the journal of the American Heart Association, Circulation, according to figures cited by brokers this week.          
Crestor's new prescription market share fell to 6.1 percent from 6.6 percent in the week ending May  27 and to 5.8 percent in the following week, London-based Code Securities investment banking house analyst Paul Diggle told Reuters.
"If U.S. market share remains below 6 percent, management will face a dilemma deciding whether to continue the very high level of
Crestor promotional support or to ease back spending to protect financial performance," Diggle said in a investors note where he rated the stock to "underperform."                                           Circulation published a critical review on Crestor in its May 23 issue. The article said Crestor had twice as many side effects, including deaths, of rival statin drugs.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.